Literature DB >> 3157440

Identification and characterization of a tumor-derived immunosuppressive glycoprotein from murine melanoma K-1735.

J B Putnam, J A Roth.   

Abstract

A suppressive immunoregulatory factor (IRF) produced by murine melanoma K-1735 M3 has been identified. Extracts from tissue or cultured cells grown in serum-medium were prepared by 3 M KCl extraction and partially purified by low-salt precipitation. IRF extracted from fresh tumor, cultured cells, and spent medium from the K-1735 cell line suppressed 3H-thymidine incorporation by splenocytes during mitogen stimulation. Cell viability was not impaired by IRF. IRF suppressed splenocyte proliferation, protein synthesis, murine IL-2-mediated blastogenesis, and mixed splenocyte responses. However, in vitro generation of allogenic cytotoxic cells was not suppressed. Significant inhibitory activity could not be extracted from normal tissues. IRF activity was reduced by treatment with proteolytic enzymes and neuraminidase and was bound by lentil lectin, indicating that the factor is a glycoprotein. IRF was heat-stable, yet labile to treatment with acid, base, or 2-mercaptoethanol. Inhibitory activity was partially characterized by preparative isoelectric focusing (pI 3.5-5.8), and the active moiety had a molecular size of 10-12 K according to HPLC. The HPLC-purified active fraction of IRF did not contain the immunosuppressive retroviral antigen p15(E). Splenocytes from animals treated with IRF in vivo demonstrated reduced responses to Con A and PHA in vitro. Suppressor cells were not identified. We have identified a low-molecular-weight glycoprotein from a murine melanoma, which suppresses a variety of immunologic responses in vitro and in vivo. IRF appears to be a potent mediator of tumor-induced immunosuppression in this model.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157440     DOI: 10.1007/bf00199715

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

Review 1.  Speculations on the role of ultraviolet radiation in the development of malignant melanoma.

Authors:  M L Kripke
Journal:  J Natl Cancer Inst       Date:  1979-09       Impact factor: 13.506

2.  Serum-derived immunosuppressive substances. I. Partial purification and range of action.

Authors:  F Miller
Journal:  Transplantation       Date:  1976-03       Impact factor: 4.939

Review 3.  Tumor induced immunosuppression.

Authors:  J A Roth
Journal:  Surg Gynecol Obstet       Date:  1983-02

4.  Suppressor cell induction factor: a new mediator released by stimulated human lymphocytes and distinct from previously described lymphokines.

Authors:  S Kasakura; M Taguchi; Y Watanabe; T Okubo; T Murachi; H Uchino; M Hanaoka
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

5.  Production of growth-inhibitory activity in serum-free medium by human monocytic leukemia cells.

Authors:  E V Gaffney; S C Tsai; M L Dell'Aquila; S E Lingenfelter
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

6.  Partial purification and characterization of a lymphocyte-inhibitory factor(s) in ascitic fluids from ovarian cancer patients.

Authors:  A D Hess; S A Gall; J R Dawson
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

7.  Detection of an inhibitor of cell division in cultures of tumour cells with immunosuppressive activity in vitro.

Authors:  J Werkmeister; R Zbroja; W McCarthy; P Hersey
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

8.  Association of impaired immune responsiveness of lymphocytes from animals bearing large tumors with a membrane-bound suppressive substance.

Authors:  B S Wang; E H Heacock; S R Onikul; Z Chang-xue; T Young; J A Mannick
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

9.  Tumor stasis factor (TSF): a possible mechanism for the regulation of tumor cell proliferation.

Authors:  J A Roth; D D Davidson; R S Ames; P D Schneider
Journal:  J Surg Res       Date:  1983-10       Impact factor: 2.192

10.  Characterization of a soluble factor that specifically suppresses the in vitro generation of cells cytotoxic for syngeneic tumor cells in mice.

Authors:  F Takei; J G Levy; D G Kilburn
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

View more
  8 in total

1.  Effects of CD4+ and CD8+ T cells in tumor-bearing mice on antibody production.

Authors:  M Shimizu; T Iwaguchi
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

2.  Inhibitors of lymphocyte activation secreted by human melanoma cell lines.

Authors:  D Giacomoni; S Ben-Efraim; F Najmabadi; S Dray
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

3.  Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide.

Authors:  M Nelson; D Nelson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens.

Authors:  Petr G Lokhov; Elena E Balashova
Journal:  J Cancer       Date:  2010-11-29       Impact factor: 4.207

6.  Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines.

Authors:  P J Guillou; C W Ramsden; S S Somers; P C Sedman
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

7.  Characterization and purification of an immunosuppressive factor produced by a small cell lung cancer cell line.

Authors:  T Ikeda; T Masuno; T Ogura; M Watanabe; T Shirasaka; H Hara; Y Tanio; I Kawase; S Kishimoto
Journal:  Jpn J Cancer Res       Date:  1991-03

Review 8.  SANTAVACTM: Summary of Research and Development.

Authors:  Petr G Lokhov; Mikayel Mkrtichyan; Grigor Mamikonyan; Elena E Balashova
Journal:  Vaccines (Basel)       Date:  2019-11-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.